DICE Therapeutics Inc - Company Profile

Powered by

All the data and insights you need on DICE Therapeutics Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date DICE Therapeutics Inc Strategy Report

  • Understand DICE Therapeutics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

DICE Therapeutics Inc: Segment Analysis

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Business Description

Dice Therapeutics Inc (DICE Therapeutics), a subsidiary of Eli Lilly and Co is a biopharmaceutical company that focuses on the discovery and development of innovative oral drug candidates to treat chronic diseases in immune disorders and other therapeutic areas. It focuses on the development of oral therapies to treat well-validated conditions in immune disorders to achieve effectiveness comparable to their systemic biologic counterparts, which have shown therapeutic benefits in immune disorders and other areas.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

DICE Therapeutics applies its R&D to enhance its proprietary DELSCAPE platform and identify exclusive oral small molecules with the potential to meet the needs of patients with chronic diseases. The company is developing its lead therapeutic candidate, DC-806 (formerly S011806), for several immune disorder indications.

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer